Arrevus is targeting ‘DnaK,’ a chaperone protein, with Designer Proline-rich antimicrobial Chaperone protein inhibitors, or “DPCs”, which damage bacterial proteins by stopping the function of these chaperones and thereby make standard antibiotics work better. In order to function, proteins need to fold in a specific way. Chaperone proteins inside of bacterial cells coordinate this folding process. During times of stress, such as exposure to antibiotics, bacteria increase the level of chaperone proteins to protect this folding process. Humans don’t have DnaK, lowering the risk to future patients and minimizing safety concerns in the clinic.